Jason Farrar
Concepts (442)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 15 | 2024 | 181 | 3.210 |
Why?
| Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.770 |
Why?
| Mutation | 15 | 2023 | 1281 | 1.750 |
Why?
| Pain Measurement | 17 | 2023 | 270 | 1.730 |
Why?
| Clinical Trials as Topic | 18 | 2018 | 486 | 1.560 |
Why?
| Ribosomal Proteins | 9 | 2021 | 24 | 1.510 |
Why?
| Pain | 14 | 2023 | 389 | 1.330 |
Why?
| Analgesics | 11 | 2018 | 116 | 1.280 |
Why?
| Midazolam | 1 | 2024 | 37 | 0.930 |
Why?
| Hypnotics and Sedatives | 1 | 2024 | 74 | 0.890 |
Why?
| Humans | 99 | 2025 | 50516 | 0.860 |
Why?
| Electroacupuncture | 4 | 2015 | 6 | 0.850 |
Why?
| Neurosurgical Procedures | 1 | 2024 | 124 | 0.850 |
Why?
| Breast Neoplasms | 5 | 2021 | 1200 | 0.840 |
Why?
| Gene Expression Profiling | 6 | 2023 | 1025 | 0.810 |
Why?
| Wounds and Injuries | 2 | 2025 | 287 | 0.770 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.760 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 11 | 0.760 |
Why?
| Testosterone | 6 | 2018 | 145 | 0.750 |
Why?
| Enoxaparin | 1 | 2021 | 31 | 0.730 |
Why?
| Female | 44 | 2025 | 27086 | 0.690 |
Why?
| Venous Thromboembolism | 1 | 2021 | 74 | 0.680 |
Why?
| Chronic Pain | 6 | 2023 | 182 | 0.670 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2021 | 213 | 0.670 |
Why?
| Diabetic Neuropathies | 3 | 2016 | 57 | 0.640 |
Why?
| Male | 44 | 2025 | 25913 | 0.640 |
Why?
| Critical Illness | 4 | 2025 | 302 | 0.630 |
Why?
| Neuralgia | 3 | 2018 | 66 | 0.630 |
Why?
| Body Weight | 1 | 2021 | 517 | 0.630 |
Why?
| Aged | 26 | 2025 | 9743 | 0.620 |
Why?
| Cyclohexanecarboxylic Acids | 2 | 2015 | 20 | 0.610 |
Why?
| Amines | 2 | 2015 | 41 | 0.600 |
Why?
| gamma-Aminobutyric Acid | 2 | 2015 | 65 | 0.590 |
Why?
| Fatigue | 4 | 2019 | 127 | 0.560 |
Why?
| RNA Processing, Post-Transcriptional | 3 | 2014 | 24 | 0.550 |
Why?
| Neuralgia, Postherpetic | 2 | 2014 | 3 | 0.540 |
Why?
| Treatment Outcome | 21 | 2023 | 5285 | 0.540 |
Why?
| Research Design | 8 | 2016 | 353 | 0.540 |
Why?
| Child, Preschool | 20 | 2021 | 3943 | 0.540 |
Why?
| Middle Aged | 23 | 2025 | 12613 | 0.520 |
Why?
| Acute Pain | 2 | 2016 | 11 | 0.510 |
Why?
| Hot Flashes | 1 | 2015 | 7 | 0.500 |
Why?
| Spinal Stenosis | 1 | 2015 | 13 | 0.500 |
Why?
| GATA1 Transcription Factor | 2 | 2017 | 7 | 0.490 |
Why?
| Hormone Replacement Therapy | 6 | 2018 | 33 | 0.490 |
Why?
| Chemotherapy, Adjuvant | 1 | 2015 | 121 | 0.480 |
Why?
| Infant | 17 | 2021 | 3629 | 0.480 |
Why?
| Adult | 22 | 2025 | 13584 | 0.480 |
Why?
| Oncogene Proteins, Fusion | 4 | 2024 | 57 | 0.480 |
Why?
| Typhoid Fever | 2 | 2011 | 3 | 0.470 |
Why?
| RNA, Ribosomal | 1 | 2014 | 19 | 0.470 |
Why?
| RNA Precursors | 1 | 2014 | 8 | 0.470 |
Why?
| Lumbar Vertebrae | 1 | 2015 | 102 | 0.460 |
Why?
| Codon, Initiator | 1 | 2014 | 1 | 0.460 |
Why?
| Child | 25 | 2025 | 6910 | 0.450 |
Why?
| Bone Neoplasms | 2 | 2023 | 179 | 0.450 |
Why?
| Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.450 |
Why?
| Point Mutation | 1 | 2014 | 62 | 0.450 |
Why?
| Pain Management | 6 | 2016 | 180 | 0.440 |
Why?
| Molar, Third | 1 | 2011 | 4 | 0.390 |
Why?
| Prognosis | 6 | 2024 | 1977 | 0.390 |
Why?
| Tooth Extraction | 1 | 2011 | 10 | 0.390 |
Why?
| Survivors | 2 | 2015 | 127 | 0.380 |
Why?
| Cryptococcus neoformans | 2 | 2010 | 27 | 0.380 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 52 | 0.370 |
Why?
| Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.360 |
Why?
| Mycological Typing Techniques | 1 | 2010 | 3 | 0.360 |
Why?
| Cerebrovascular Circulation | 1 | 2011 | 132 | 0.350 |
Why?
| DNA, Fungal | 1 | 2010 | 46 | 0.350 |
Why?
| Sexual Behavior | 3 | 2016 | 117 | 0.350 |
Why?
| Gene Deletion | 1 | 2011 | 261 | 0.350 |
Why?
| Pain, Postoperative | 1 | 2011 | 163 | 0.350 |
Why?
| Brain Mapping | 1 | 2011 | 232 | 0.350 |
Why?
| Arthralgia | 3 | 2014 | 45 | 0.340 |
Why?
| Practice Guidelines as Topic | 4 | 2015 | 468 | 0.330 |
Why?
| Adolescent | 16 | 2025 | 6446 | 0.330 |
Why?
| Polymorphism, Single Nucleotide | 5 | 2013 | 474 | 0.330 |
Why?
| Drug Resistance, Bacterial | 2 | 2010 | 72 | 0.330 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2023 | 573 | 0.320 |
Why?
| Dysentery, Bacillary | 1 | 2009 | 2 | 0.320 |
Why?
| Shigella | 1 | 2009 | 7 | 0.320 |
Why?
| Acupuncture Therapy | 1 | 2009 | 4 | 0.320 |
Why?
| Cephalosporins | 1 | 2009 | 39 | 0.310 |
Why?
| Osteoarthritis, Knee | 2 | 2023 | 96 | 0.310 |
Why?
| Biomedical Research | 2 | 2015 | 244 | 0.310 |
Why?
| Dogs | 1 | 2008 | 186 | 0.300 |
Why?
| Vietnam | 7 | 2010 | 27 | 0.300 |
Why?
| Disability Evaluation | 3 | 2019 | 92 | 0.290 |
Why?
| Radiotherapy | 1 | 2009 | 125 | 0.290 |
Why?
| Double-Blind Method | 7 | 2023 | 708 | 0.290 |
Why?
| Case-Control Studies | 5 | 2017 | 1155 | 0.290 |
Why?
| Quality of Life | 8 | 2019 | 852 | 0.290 |
Why?
| Severity of Illness Index | 7 | 2024 | 978 | 0.280 |
Why?
| Young Adult | 11 | 2025 | 4107 | 0.280 |
Why?
| Health Status | 2 | 2017 | 299 | 0.280 |
Why?
| DNA Methylation | 6 | 2023 | 550 | 0.280 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 43 | 0.280 |
Why?
| Anti-Inflammatory Agents | 2 | 2019 | 163 | 0.270 |
Why?
| Stress, Psychological | 2 | 2014 | 266 | 0.270 |
Why?
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2017 | 6 | 0.270 |
Why?
| Prospective Studies | 6 | 2024 | 2378 | 0.260 |
Why?
| Disease Models, Animal | 3 | 2021 | 1436 | 0.260 |
Why?
| Intensive Care Units | 2 | 2024 | 225 | 0.260 |
Why?
| Aromatase Inhibitors | 3 | 2014 | 17 | 0.260 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2025 | 4 | 0.250 |
Why?
| Lipomatosis | 1 | 2025 | 6 | 0.250 |
Why?
| Bone Marrow Diseases | 1 | 2025 | 11 | 0.250 |
Why?
| Kidney Function Tests | 1 | 2025 | 51 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 405 | 0.240 |
Why?
| Age Factors | 4 | 2021 | 1110 | 0.240 |
Why?
| Creatinine | 1 | 2025 | 145 | 0.240 |
Why?
| Walking | 2 | 2016 | 100 | 0.240 |
Why?
| Nutritional Support | 1 | 2024 | 35 | 0.230 |
Why?
| Lymphoma | 1 | 2025 | 67 | 0.230 |
Why?
| Cystitis, Interstitial | 1 | 2023 | 11 | 0.220 |
Why?
| Hemophilia A | 1 | 2024 | 25 | 0.220 |
Why?
| Gene Rearrangement | 1 | 2024 | 65 | 0.210 |
Why?
| Neuromuscular Blockade | 1 | 2023 | 15 | 0.210 |
Why?
| Encephalitis, Japanese | 1 | 2003 | 2 | 0.210 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 161 | 0.210 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2024 | 326 | 0.210 |
Why?
| Genotype | 4 | 2013 | 532 | 0.210 |
Why?
| Consensus | 1 | 2024 | 160 | 0.210 |
Why?
| Anti-Bacterial Agents | 1 | 2009 | 745 | 0.210 |
Why?
| Osteosarcoma | 1 | 2023 | 45 | 0.210 |
Why?
| Tandem Mass Spectrometry | 1 | 2024 | 238 | 0.210 |
Why?
| Interferon-alpha | 1 | 2003 | 47 | 0.210 |
Why?
| Viruses | 2 | 2015 | 22 | 0.210 |
Why?
| Enteral Nutrition | 1 | 2023 | 150 | 0.200 |
Why?
| Chromosome Aberrations | 3 | 2017 | 280 | 0.200 |
Why?
| Cluster Analysis | 3 | 2011 | 219 | 0.200 |
Why?
| Aged, 80 and over | 5 | 2018 | 3227 | 0.200 |
Why?
| Azacitidine | 2 | 2023 | 34 | 0.200 |
Why?
| Blood Glucose | 1 | 2024 | 447 | 0.190 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 15 | 0.190 |
Why?
| Antiviral Agents | 1 | 2003 | 170 | 0.190 |
Why?
| Cross-Sectional Studies | 4 | 2019 | 1608 | 0.190 |
Why?
| Drug Dosage Calculations | 1 | 2021 | 11 | 0.190 |
Why?
| Salmonella typhi | 2 | 2011 | 4 | 0.180 |
Why?
| Diabetes Mellitus | 1 | 2024 | 279 | 0.180 |
Why?
| Co-Repressor Proteins | 1 | 2021 | 17 | 0.180 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 74 | 0.180 |
Why?
| Androgens | 2 | 2018 | 70 | 0.180 |
Why?
| Erythrocyte Transfusion | 1 | 2021 | 52 | 0.180 |
Why?
| Neoplasms | 2 | 2009 | 1255 | 0.180 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 106 | 0.180 |
Why?
| Placebos | 4 | 2016 | 87 | 0.180 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 36 | 0.180 |
Why?
| Injury Severity Score | 1 | 2021 | 164 | 0.180 |
Why?
| B-Lymphocytes | 1 | 2021 | 171 | 0.180 |
Why?
| Kidney | 1 | 2025 | 696 | 0.170 |
Why?
| Registries | 2 | 2018 | 563 | 0.170 |
Why?
| Retrospective Studies | 6 | 2025 | 6264 | 0.170 |
Why?
| Chromatin | 1 | 2021 | 137 | 0.170 |
Why?
| Leucine | 1 | 2020 | 117 | 0.170 |
Why?
| MicroRNAs | 2 | 2021 | 344 | 0.160 |
Why?
| Blood Transfusion | 1 | 2020 | 129 | 0.160 |
Why?
| Systemic Vasculitis | 1 | 2019 | 2 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 2 | 2021 | 1372 | 0.160 |
Why?
| Pain, Intractable | 2 | 2010 | 8 | 0.160 |
Why?
| Ribosomes | 2 | 2009 | 22 | 0.160 |
Why?
| Recurrence | 2 | 2022 | 659 | 0.160 |
Why?
| Sex Factors | 1 | 2021 | 711 | 0.150 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2018 | 22 | 0.150 |
Why?
| Research Report | 1 | 2018 | 16 | 0.150 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 418 | 0.150 |
Why?
| Evidence-Based Medicine | 2 | 2010 | 253 | 0.150 |
Why?
| Incidence | 1 | 2021 | 1032 | 0.140 |
Why?
| Anxiety | 2 | 2023 | 285 | 0.140 |
Why?
| Feasibility Studies | 3 | 2020 | 391 | 0.140 |
Why?
| Induction Chemotherapy | 1 | 2017 | 59 | 0.140 |
Why?
| Sensory Thresholds | 1 | 2017 | 18 | 0.140 |
Why?
| Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.140 |
Why?
| Agammaglobulinemia | 1 | 1996 | 9 | 0.140 |
Why?
| X Chromosome | 1 | 1996 | 12 | 0.140 |
Why?
| Genome, Human | 2 | 2021 | 109 | 0.140 |
Why?
| Infant, Newborn | 4 | 2023 | 2749 | 0.130 |
Why?
| Anemia | 1 | 2017 | 67 | 0.130 |
Why?
| HIV Infections | 2 | 2010 | 352 | 0.130 |
Why?
| Phenotype | 3 | 2021 | 739 | 0.130 |
Why?
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
| Sexual Dysfunction, Physiological | 1 | 2016 | 17 | 0.130 |
Why?
| Hemoglobins | 1 | 2017 | 109 | 0.130 |
Why?
| CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.130 |
Why?
| Cell Proliferation | 4 | 2021 | 985 | 0.130 |
Why?
| Inservice Training | 1 | 2016 | 32 | 0.130 |
Why?
| Animals | 9 | 2023 | 13124 | 0.130 |
Why?
| Neutropenia | 1 | 1996 | 116 | 0.130 |
Why?
| Health Planning Guidelines | 2 | 2007 | 14 | 0.130 |
Why?
| Low Back Pain | 1 | 2016 | 28 | 0.130 |
Why?
| Longitudinal Studies | 3 | 2019 | 735 | 0.130 |
Why?
| Consensus Development Conferences as Topic | 1 | 2015 | 13 | 0.130 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 572 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2016 | 109 | 0.120 |
Why?
| Needles | 1 | 2015 | 25 | 0.120 |
Why?
| Influenza A Virus, H5N1 Subtype | 1 | 2015 | 1 | 0.120 |
Why?
| Time Factors | 5 | 2015 | 2935 | 0.120 |
Why?
| Exercise Test | 1 | 2015 | 131 | 0.120 |
Why?
| Hypopituitarism | 1 | 2014 | 17 | 0.120 |
Why?
| Placebo Effect | 1 | 2014 | 17 | 0.120 |
Why?
| Nepal | 2 | 2011 | 12 | 0.120 |
Why?
| Intention to Treat Analysis | 1 | 2014 | 28 | 0.120 |
Why?
| Pilot Projects | 2 | 2020 | 699 | 0.120 |
Why?
| Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.120 |
Why?
| Gonadal Steroid Hormones | 1 | 2014 | 41 | 0.120 |
Why?
| K562 Cells | 1 | 2014 | 40 | 0.120 |
Why?
| Transcription Factors | 3 | 2024 | 565 | 0.120 |
Why?
| Virus Diseases | 1 | 2015 | 42 | 0.120 |
Why?
| Risk Factors | 2 | 2021 | 3723 | 0.110 |
Why?
| Analgesics, Opioid | 2 | 2012 | 575 | 0.110 |
Why?
| Exercise | 1 | 2018 | 516 | 0.110 |
Why?
| Chromosome Mapping | 3 | 2011 | 153 | 0.110 |
Why?
| Respiratory Tract Infections | 1 | 2015 | 78 | 0.110 |
Why?
| Skin | 1 | 2017 | 389 | 0.110 |
Why?
| Leukemia, Myeloid | 1 | 2014 | 44 | 0.110 |
Why?
| Molecular Epidemiology | 2 | 2010 | 36 | 0.110 |
Why?
| Influenza, Human | 1 | 2015 | 86 | 0.110 |
Why?
| Anemia, Macrocytic | 1 | 2013 | 2 | 0.110 |
Why?
| United States | 4 | 2014 | 4955 | 0.110 |
Why?
| Motor Activity | 1 | 2014 | 225 | 0.110 |
Why?
| Prescription Drug Misuse | 1 | 2013 | 34 | 0.110 |
Why?
| Cytogenetic Analysis | 1 | 2013 | 74 | 0.110 |
Why?
| Base Sequence | 3 | 2010 | 639 | 0.110 |
Why?
| Aging | 1 | 2018 | 694 | 0.100 |
Why?
| Endpoint Determination | 2 | 2013 | 26 | 0.100 |
Why?
| Prevalence | 3 | 2018 | 971 | 0.100 |
Why?
| Depression | 2 | 2016 | 582 | 0.100 |
Why?
| Self Report | 1 | 2014 | 206 | 0.100 |
Why?
| RNA, Messenger | 4 | 2021 | 1089 | 0.100 |
Why?
| Genomics | 1 | 2014 | 279 | 0.100 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 602 | 0.100 |
Why?
| Neurology | 1 | 2012 | 42 | 0.100 |
Why?
| Chromosome Deletion | 2 | 2013 | 134 | 0.100 |
Why?
| Pain Perception | 1 | 2011 | 5 | 0.100 |
Why?
| Organotechnetium Compounds | 1 | 2011 | 7 | 0.100 |
Why?
| Pennsylvania | 1 | 2011 | 35 | 0.100 |
Why?
| Salmonella paratyphi A | 1 | 2011 | 1 | 0.100 |
Why?
| Haploinsufficiency | 1 | 2011 | 14 | 0.100 |
Why?
| Libido | 3 | 2016 | 9 | 0.100 |
Why?
| Mosaicism | 1 | 2011 | 18 | 0.100 |
Why?
| Genotyping Techniques | 1 | 2011 | 20 | 0.100 |
Why?
| Blotting, Northern | 1 | 2011 | 110 | 0.100 |
Why?
| Water Supply | 1 | 2011 | 22 | 0.100 |
Why?
| Cysteine | 1 | 2011 | 50 | 0.090 |
Why?
| Endemic Diseases | 1 | 2011 | 22 | 0.090 |
Why?
| Water Microbiology | 1 | 2011 | 30 | 0.090 |
Why?
| Microbial Sensitivity Tests | 2 | 2010 | 269 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2008 | 208 | 0.090 |
Why?
| Encephalitis, Viral | 1 | 2010 | 6 | 0.090 |
Why?
| Genome-Wide Association Study | 1 | 2011 | 163 | 0.090 |
Why?
| Neoplastic Stem Cells | 2 | 2022 | 98 | 0.090 |
Why?
| Phylogeny | 1 | 2011 | 236 | 0.090 |
Why?
| Radiopharmaceuticals | 1 | 2011 | 204 | 0.090 |
Why?
| Urban Population | 1 | 2011 | 151 | 0.090 |
Why?
| Dengue | 1 | 2010 | 3 | 0.090 |
Why?
| Viremia | 1 | 2010 | 22 | 0.090 |
Why?
| Bacterial Typing Techniques | 1 | 2010 | 38 | 0.090 |
Why?
| Daunorubicin | 2 | 2022 | 11 | 0.090 |
Why?
| WT1 Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| Reproducibility of Results | 2 | 2016 | 1199 | 0.080 |
Why?
| Cytarabine | 2 | 2022 | 37 | 0.080 |
Why?
| Antibodies, Viral | 1 | 2010 | 93 | 0.080 |
Why?
| DNA, Bacterial | 1 | 2010 | 186 | 0.080 |
Why?
| Outpatients | 2 | 2024 | 117 | 0.080 |
Why?
| Viral Nonstructural Proteins | 1 | 2010 | 56 | 0.080 |
Why?
| Chronic Disease | 5 | 2011 | 574 | 0.080 |
Why?
| Cohort Studies | 2 | 2016 | 1452 | 0.080 |
Why?
| Guidelines as Topic | 1 | 2009 | 109 | 0.080 |
Why?
| Brain | 1 | 2017 | 1323 | 0.080 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2008 | 18 | 0.080 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 138 | 0.070 |
Why?
| Pedigree | 1 | 2008 | 119 | 0.070 |
Why?
| Social Participation | 2 | 2019 | 5 | 0.070 |
Why?
| Opioid-Related Disorders | 1 | 2012 | 393 | 0.070 |
Why?
| Chromosomes, Human, Pair 6 | 1 | 2007 | 14 | 0.070 |
Why?
| Wilms Tumor | 1 | 2007 | 18 | 0.070 |
Why?
| Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.070 |
Why?
| Oxycodone | 1 | 2007 | 27 | 0.070 |
Why?
| Health Care Surveys | 1 | 2007 | 175 | 0.070 |
Why?
| Amino Acid Sequence | 1 | 2008 | 574 | 0.070 |
Why?
| Molecular Sequence Data | 1 | 2008 | 778 | 0.070 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2007 | 95 | 0.070 |
Why?
| Focus Groups | 2 | 2023 | 194 | 0.070 |
Why?
| DNA Helicases | 1 | 2008 | 146 | 0.070 |
Why?
| Mice | 4 | 2023 | 5687 | 0.070 |
Why?
| Cell Differentiation | 2 | 2021 | 640 | 0.070 |
Why?
| Models, Biological | 1 | 2009 | 716 | 0.070 |
Why?
| Kidney Neoplasms | 1 | 2007 | 174 | 0.060 |
Why?
| Cell Line | 1 | 2008 | 988 | 0.060 |
Why?
| Comorbidity | 1 | 2007 | 623 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2005 | 84 | 0.060 |
Why?
| Tacrolimus | 1 | 2005 | 53 | 0.060 |
Why?
| Insulin, Isophane | 1 | 2024 | 1 | 0.060 |
Why?
| Transcriptome | 2 | 2017 | 314 | 0.060 |
Why?
| Glomerular Filtration Rate | 1 | 2025 | 119 | 0.060 |
Why?
| DNA | 1 | 2008 | 535 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2005 | 79 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2020 | 2242 | 0.060 |
Why?
| Erectile Dysfunction | 2 | 2016 | 90 | 0.060 |
Why?
| Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
| Minor Histocompatibility Antigens | 1 | 2024 | 17 | 0.060 |
Why?
| Hyperglycemia | 1 | 2024 | 81 | 0.060 |
Why?
| Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.060 |
Why?
| Proto-Oncogenes | 1 | 2024 | 27 | 0.060 |
Why?
| DEAD-box RNA Helicases | 1 | 2024 | 33 | 0.060 |
Why?
| Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.050 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 181 | 0.050 |
Why?
| Nuclear Pore Complex Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| Autoantibodies | 1 | 2024 | 117 | 0.050 |
Why?
| CpG Islands | 1 | 2023 | 108 | 0.050 |
Why?
| Hypoglycemic Agents | 1 | 2024 | 173 | 0.050 |
Why?
| Ambulatory Care | 1 | 2024 | 230 | 0.050 |
Why?
| Treatment Failure | 1 | 2003 | 118 | 0.050 |
Why?
| Apoptosis | 1 | 2008 | 1097 | 0.050 |
Why?
| Disease Management | 1 | 2024 | 178 | 0.050 |
Why?
| Computational Biology | 1 | 2024 | 215 | 0.050 |
Why?
| Hemorrhage | 1 | 2024 | 197 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2025 | 930 | 0.050 |
Why?
| Insulin | 1 | 2024 | 467 | 0.050 |
Why?
| Algorithms | 2 | 2017 | 628 | 0.050 |
Why?
| Vaccination | 1 | 2024 | 280 | 0.050 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| Core Binding Factor beta Subunit | 1 | 2021 | 3 | 0.050 |
Why?
| Blood Coagulation | 1 | 2002 | 60 | 0.050 |
Why?
| Myosin Heavy Chains | 1 | 2021 | 21 | 0.050 |
Why?
| RNA | 1 | 2022 | 163 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2003 | 476 | 0.050 |
Why?
| Qualitative Research | 1 | 2023 | 348 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2021 | 29 | 0.050 |
Why?
| Enhancer Elements, Genetic | 1 | 2021 | 58 | 0.040 |
Why?
| Acetylation | 1 | 2021 | 94 | 0.040 |
Why?
| RNA-Binding Proteins | 1 | 2021 | 118 | 0.040 |
Why?
| Trans-Activators | 1 | 2021 | 134 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2021 | 119 | 0.040 |
Why?
| HEK293 Cells | 1 | 2021 | 213 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 296 | 0.040 |
Why?
| Up-Regulation | 1 | 2021 | 446 | 0.040 |
Why?
| Receptors, GABA-A | 1 | 2019 | 12 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2021 | 181 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 562 | 0.040 |
Why?
| Risk Assessment | 2 | 2015 | 1269 | 0.040 |
Why?
| Oxidative Stress | 1 | 2024 | 772 | 0.040 |
Why?
| Hematopoietic Stem Cells | 1 | 2021 | 197 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1398 | 0.040 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 577 | 0.040 |
Why?
| Protein Binding | 1 | 2021 | 654 | 0.040 |
Why?
| Histones | 1 | 2021 | 297 | 0.040 |
Why?
| Emotions | 2 | 2014 | 167 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 641 | 0.040 |
Why?
| Patient Selection | 2 | 2010 | 259 | 0.040 |
Why?
| Etoposide | 1 | 2017 | 77 | 0.040 |
Why?
| Drug Administration Routes | 1 | 2017 | 10 | 0.040 |
Why?
| Erythroid Cells | 1 | 2017 | 5 | 0.040 |
Why?
| Genes, Dominant | 1 | 2017 | 19 | 0.040 |
Why?
| Erythropoiesis | 1 | 2017 | 15 | 0.040 |
Why?
| Genes, X-Linked | 1 | 2017 | 7 | 0.040 |
Why?
| Drug Monitoring | 1 | 2017 | 79 | 0.030 |
Why?
| Models, Genetic | 1 | 2017 | 172 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 1996 | 88 | 0.030 |
Why?
| Cognition | 1 | 2019 | 346 | 0.030 |
Why?
| Statistics as Topic | 1 | 2016 | 88 | 0.030 |
Why?
| Prostate-Specific Antigen | 1 | 2016 | 44 | 0.030 |
Why?
| Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| Reference Values | 1 | 2016 | 307 | 0.030 |
Why?
| Meteorological Concepts | 1 | 2015 | 1 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 465 | 0.030 |
Why?
| Congresses as Topic | 1 | 2015 | 48 | 0.030 |
Why?
| Pharynx | 1 | 2015 | 31 | 0.030 |
Why?
| China | 1 | 2015 | 90 | 0.030 |
Why?
| Family Health | 1 | 2015 | 77 | 0.030 |
Why?
| Androstadienes | 1 | 2014 | 11 | 0.030 |
Why?
| DNA, Viral | 1 | 2015 | 136 | 0.030 |
Why?
| Nitriles | 1 | 2014 | 52 | 0.030 |
Why?
| Sample Size | 1 | 2014 | 39 | 0.030 |
Why?
| Publishing | 1 | 2014 | 40 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2017 | 372 | 0.030 |
Why?
| Child Health Services | 1 | 2015 | 78 | 0.030 |
Why?
| Methylation | 1 | 2014 | 118 | 0.030 |
Why?
| Acupuncture Points | 1 | 2013 | 3 | 0.030 |
Why?
| Gait | 1 | 2014 | 89 | 0.030 |
Why?
| Population | 1 | 2013 | 9 | 0.030 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2013 | 46 | 0.030 |
Why?
| Triazoles | 1 | 2014 | 113 | 0.030 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2013 | 15 | 0.030 |
Why?
| Waiting Lists | 1 | 2013 | 59 | 0.030 |
Why?
| Substance Abuse Detection | 1 | 2013 | 90 | 0.030 |
Why?
| Cells, Cultured | 1 | 2017 | 1571 | 0.030 |
Why?
| Terminology as Topic | 1 | 2013 | 67 | 0.030 |
Why?
| Models, Statistical | 1 | 2014 | 226 | 0.030 |
Why?
| Risk | 1 | 2013 | 324 | 0.030 |
Why?
| Immunologic Factors | 1 | 2013 | 111 | 0.030 |
Why?
| Internationality | 1 | 2012 | 41 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2013 | 591 | 0.020 |
Why?
| Thalidomide | 1 | 2013 | 378 | 0.020 |
Why?
| Virology | 1 | 2010 | 7 | 0.020 |
Why?
| Coma | 1 | 2010 | 16 | 0.020 |
Why?
| Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| Flucytosine | 1 | 2010 | 13 | 0.020 |
Why?
| DNA Gyrase | 1 | 2010 | 4 | 0.020 |
Why?
| Reagent Kits, Diagnostic | 1 | 2010 | 17 | 0.020 |
Why?
| Immunoassay | 1 | 2010 | 20 | 0.020 |
Why?
| High-Throughput Screening Assays | 1 | 2010 | 35 | 0.020 |
Why?
| Amphotericin B | 1 | 2010 | 102 | 0.020 |
Why?
| Haplotypes | 1 | 2010 | 83 | 0.020 |
Why?
| RNA, Viral | 1 | 2010 | 107 | 0.020 |
Why?
| Point-of-Care Systems | 1 | 2010 | 57 | 0.020 |
Why?
| Random Allocation | 1 | 2010 | 289 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 370 | 0.020 |
Why?
| Retroviridae | 1 | 2008 | 9 | 0.020 |
Why?
| Probability Theory | 1 | 2008 | 2 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2009 | 444 | 0.020 |
Why?
| Anaerobiosis | 1 | 2008 | 19 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2008 | 46 | 0.020 |
Why?
| Least-Squares Analysis | 1 | 2008 | 40 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2008 | 105 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2010 | 861 | 0.020 |
Why?
| Ankyrin Repeat | 1 | 2007 | 2 | 0.020 |
Why?
| Antifungal Agents | 1 | 2010 | 331 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2007 | 69 | 0.020 |
Why?
| Pain Clinics | 1 | 2007 | 4 | 0.020 |
Why?
| Signal Transduction | 1 | 2014 | 1624 | 0.020 |
Why?
| Delayed-Action Preparations | 1 | 2007 | 56 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 909 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2008 | 583 | 0.020 |
Why?
| Bacterial Proteins | 1 | 2010 | 367 | 0.020 |
Why?
| Activities of Daily Living | 1 | 2007 | 177 | 0.020 |
Why?
| Fibroblasts | 1 | 2008 | 336 | 0.020 |
Why?
| Absorption | 1 | 2005 | 22 | 0.020 |
Why?
| Analysis of Variance | 1 | 2007 | 552 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2007 | 278 | 0.020 |
Why?
| Administration, Topical | 1 | 2005 | 57 | 0.020 |
Why?
| Oxygen | 1 | 2008 | 323 | 0.020 |
Why?
| Mental Health | 1 | 2007 | 228 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2005 | 136 | 0.020 |
Why?
| Skin Diseases | 1 | 2005 | 112 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 510 | 0.010 |
Why?
| Patient Acceptance of Health Care | 1 | 2007 | 342 | 0.010 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 833 | 0.010 |
Why?
| Blood Coagulation Tests | 1 | 2002 | 20 | 0.010 |
Why?
| World Health Organization | 1 | 2002 | 51 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|